x

Global Elapegademase-lvlr Market Research Report 2019

Published Date: 2019-06-20   |   Pages: 98   |   Tables: 120   | Report Id: 1185572   | Hits: 323 |   Pharma & Healthcare

category cover


Revcovi (elapegademase-lvlr) is a new enzyme replacement therapy indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.

In 2018, global revenue of Elapegademase-lvlr is nearly 11 M USD and will be 16.9 million USD, with a CAGR of 3.5% between 2019 and 2025.


This report focuses on Elapegademase-lvlr volume and value at global level, regional level and company level. From a global perspective, this report represents overall Elapegademase-lvlr market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, and Japan.


At company level, this report focuses on the sales, ex-factory price, revenue and market share for each manufacturer covered in this report.


The following manufacturers are covered:

Leadiant Biosciences

Orchard Therapeutics

Teijin Pharma


Segment by Regions

North America

Europe

Japan

Rest of World


Segment by Type

Revcovi

Strimvelis

Adagen


Segment by Application

Pediatric

Adult



Licenses Type

Only one user can access the report
Multiple users can access the report

Why QYR

 Fastest report delivery service
 More than 10 years of vast experience
 Operational for 24 * 7 & 365 days
 In-depth and comprehensive analysis
 Excellent after sales support
 Owns large database

Need Help ?

Global Elapegademase lvlr market

QYR Clients

  • csl
  • croozer
  • crital alert
  • cristal
  • corveneng
  • coperion
  • contijpi medical
  • compass minerals
  • compass minerals
  • compass minerals
  • compass minerals
  • compass minerals
  • compass minerals
  • compass minerals
  • compass minerals
  • compass minerals
  • compass minerals
  • compass minerals
  • compass minerals
  • compass minerals
More Clients...